Phase III Study Completes Patient Recruitment

On May 2, 2017 Ablynx announced that it has successfully completed patient recruitment in the multi-national, double-blind, placebo-controlled Phase III HERCULES study of caplacizumab to treat acquired TTP. If approved, this drug will be the first therapeutic specifically indicated for the disease.

View the full press release.